1 Recommendations

1.1 Sorafenib is recommended as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh gradeĀ A liver impairment, only if the company provides sorafenib within the agreed commercial access arrangement.

1.2 This recommendation is not intended to affect treatment with sorafenib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)